



# Exponent Inc (EXPO)

Updated February 8<sup>th</sup>, 2026 by Quinn Mohammed

## Key Metrics

|                             |      |                                            |             |                                           |             |
|-----------------------------|------|--------------------------------------------|-------------|-------------------------------------------|-------------|
| <b>Current Price:</b>       | \$80 | <b>5 Year CAGR Estimate:</b>               | 10.5%       | <b>Market Cap:</b>                        | \$4.0 B     |
| <b>Fair Value Price:</b>    | \$93 | <b>5 Year Growth Estimate:</b>             | 6.0%        | <b>Ex-Dividend Date<sup>1</sup>:</b>      | 03//06/2026 |
| <b>% Fair Value:</b>        | 86%  | <b>5 Year Valuation Multiple Estimate:</b> | 3.0%        | <b>Dividend Payment Date<sup>1</sup>:</b> | 03/20/2026  |
| <b>Dividend Yield:</b>      | 1.6% | <b>5 Year Price Target</b>                 | \$124       | <b>Years of Dividend Growth:</b>          | 13          |
| <b>Dividend Risk Score:</b> | C    | <b>Sector:</b>                             | Industrials | <b>Rating:</b>                            | Hold        |

## Overview & Current Events

Exponent Inc. is a science and engineering consulting company that provides complex solutions on a project-by-project basis. The organization consists of scientists, physicians, engineers, and regulatory consultants which bring together more than 90 technical disciplines which address the complicated issues facing industry and government. Exponent trades on the NASDAQ under the ticker symbol EXPO. The company was founded in Silicon Valley and today is headquartered in Menlo Park, California. The corporation has offices in the United States, Europe, and Asia.

Exponent operates in two segments, the first of which is engineering and other sciences, which provides servicing for biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. Then, the environmental and health segment consists of chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences, and others. EXPO has a market capitalization of \$4.0 billion.

On February 5<sup>th</sup>, 2026, Exponent announced a \$0.31 quarterly dividend, a one cent increase, and the thirteenth consecutive annual dividend increase.

Exponent reported fourth quarter 2025 results on February 5<sup>th</sup>, 2026, for the period ending January 2<sup>nd</sup>, 2026. The company reported total revenues improved by 8% year-over-year to \$147 million. Net income increased by 4% to \$25 million from \$24 million in the prior-year quarter. Net income per diluted share of \$0.49 also jumped 7%.

Leadership initiated its FY 2026 outlook. For the full year, EXPO expects revenues before reimbursements to grow by high-single digits, and anticipates an EBITDA margin of 27.6% to 28.1% of revenues before reimbursements.

## Growth on a Per-Share Basis

| Year                      | 2016   | 2017   | 2018   | 2019   | 2020   | 2021   | 2022   | 2023   | 2024   | 2025   | 2026          | 2031          |
|---------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|---------------|---------------|
| <b>EPS</b>                | \$0.88 | \$0.77 | \$1.33 | \$1.53 | \$1.55 | \$1.90 | \$1.96 | \$1.94 | \$2.11 | \$2.07 | <b>\$2.44</b> | <b>\$3.27</b> |
| <b>DPS</b>                | \$0.36 | \$0.42 | \$0.52 | \$0.64 | \$0.76 | \$0.80 | \$0.96 | \$1.04 | \$1.12 | \$1.20 | <b>\$1.24</b> | <b>\$1.66</b> |
| <b>Shares<sup>2</sup></b> | 51.2   | 51.5   | 51.5   | 51.8   | 51.8   | 52.1   | 52.3   | 51.6   | 51.6   | 51.2   | <b>51.0</b>   | <b>51.5</b>   |

Exponent has a stable track record of earnings growth and has grown at a robust rate in the trailing nine-year period. Over the last nine and five years, Exponent has increased its EPS at 10% and 6% CAGRs, respectively. We project Exponent will increase its earnings-per-share by 6% per year into 2031. The company's results have remained stable and continued growing, even throughout the COVID pandemic.

Growth will be driven mostly by new business and clientele. Exponent's interdisciplinary proactive solutions is experiencing increasing demand in safety, health, sustainability, and reliability. Both industry and government are advancing their missions, designing novel products, navigating new regulatory challenges, innovating, and evaluating new paradigms and processes, which Exponent expects to capitalize on. Both segments benefit from increased activity in litigation related projects and support. In the engineering segment, demand for solutions in electric vehicles and energy storage continues to rise over the long term.

<sup>1</sup> Estimate based on last year's date

<sup>2</sup> in millions.

*Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.*



# Exponent Inc (EXPO)

Updated February 8<sup>th</sup>, 2026 by Quinn Mohammed

The share count has remained stable; thus, shareholders have not been heavily diluted in the last decade. Exponent has grown its quarterly dividend for thirteen consecutive years, and we estimate it will grow 6% annually from here on out.

## Valuation Analysis

| Year      | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Now  | 2031 |
|-----------|------|------|------|------|------|------|------|------|------|------|------|------|
| Avg. P/E  | 30.1 | 42.1 | 34.8 | 40.0 | 49.1 | 54.4 | 48.8 | 46.8 | 44.9 | 36.9 | 32.7 | 38.0 |
| Avg. Yld. | 1.4% | 1.3% | 1.1% | 1.0% | 1.0% | 0.8% | 0.9% | 1.1% | 1.2% | 1.5% | 1.6% | 1.3% |

Exponent trades at 32.7 times this year's expected net income right now. Shares trade below their ten- and five-year average PE ratios of 42.8- and 46.4-times earnings. We see fair value at 38.0 times net income, which would result in a 3.0% annual gain due to multiple expansion.

## Safety, Quality, Competitive Advantage, & Recession Resiliency

| Year   | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2031 |
|--------|------|------|------|------|------|------|------|------|------|------|------|------|
| Payout | 41%  | 55%  | 39%  | 42%  | 49%  | 42%  | 49%  | 54%  | 53%  | 58%  | 51%  | 51%  |


The company's payout ratio has steadily increased since it began paying a dividend in 2013. The estimated 2026 payout ratio of 51% is secure, and in line with its recent average payout ratio. During the great financial crisis, the company remained profitable, and, in fact, continued to grow earnings the entire time.

Exponent operates in a low barrier to entry business, and competition is increasing for many of their technical disciplines. The marketplace for Exponent's services is fragmented, so it faces multiple sources of competition in providing services. We don't see a strong competitive advantage in Exponent, nevertheless, the company has performed very well.

## Final Thoughts & Recommendation

Exponent has increased its earnings-per-share by double digits in the last decade. Although there is still plenty of room for expansion, we don't expect the same rates of growth as in the past. We forecast 6% earnings-per-share growth. At the current price, we see Exponent as trading at a 14% discount to fair value and forecast annualized total returns of 10.5%. Exponent maintains its hold rating.

## Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Exponent Inc (EXPO)

Updated February 8<sup>th</sup>, 2026 by Quinn Mohammed

## Income Statement Metrics

| Year             | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024  | 2025  |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Revenue          | 315   | 348   | 380   | 417   | 400   | 466   | 513   | 537   | 558   | 582   |
| SG&A Exp.        | 209   | 228   | 233   | 273   | 263   | 293   | 288   | 344   | 352   | 26    |
| D&A Exp.         | 6     | 6     | 6     | 7     | 7     | ---   |       |       | NA    |       |
| Operating Profit | 62    | 72    | 91    | 85    | 83    | 109   | 141   | 111   | 119   | 120   |
| Operating Margin | 19.6% | 20.7% | 24.1% | 20.4% | 20.8% | 23.4% | 27%   | 20.7% | 20.7% | 20.6% |
| Net Profit       | 47    | 41    | 72    | 82    | 83    | 101   | 102   | 100   | 109   | 106   |
| Net Margin       | 15.1% | 11.9% | 19.0% | 19.8% | 20.6% | 21.7% | 19.9% | 18.6% | 18.6% | 18.2% |
| Free Cash Flow   | 53    | 63    | 75    | 85    | 98    |       |       |       | NA    | 0     |
| Income Tax       | 22    | 41    | 21    | 22    | 14    | 25    | 30    | 36    | 38    | 41    |

## Balance Sheet Metrics

| Year                 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|----------------------|------|------|------|------|------|------|------|------|------|------|
| Total Assets         | 404  | 440  | 469  | 563  | 580  | 684  | 587  | 647  | 777  | 778  |
| Cash & Equivalents   | 115  | 125  | 127  | 176  | 198  | 298  | 161  | 187  | 258  | 222  |
| Accounts Receivable  | 61   | 78   | 74   | 86   | 80   | 140  | 170  | 167  | 161  | 182  |
| Goodwill & Int. Ass. | 9    | 9    | 9    | 9    | 9    | 9    | 9    | 9    | 8    | 9    |
| Total Liabilities    | 130  | 151  | 155  | 213  | 219  | 267  | 266  | 291  | 356  | 387  |
| Accounts Payable     | 3    | 3    | 3    | 5    | 3    | 25   | 29   | 22   | 22   | 31   |
| Long-Term Debt       | 0    | 0    | 0    | 0    | 0    | 0    | 0    |      | 0    | 76   |
| Shareholder's Equity | 273  | 289  | 314  | 350  | 361  | 417  | 321  | 356  | 421  | 421  |
| D/E Ratio            | 0    | 0    | 0    | 0    | 0    | 0    | 0    |      |      | 0.21 |

## Profitability & Per Share Metrics

| Year             | 2016  | 2017  | 2018  | 2019  | 2020  | 2021  | 2022  | 2023  | 2024  | 2025  |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Return on Assets | 12.0% | 9.8%  | 15.9% | 16.0% | 14.4% | 16.0% | 16.1% | 16.3% | 16.3% | 13.4% |
| Return on Equity | 17.7% | 14.7% | 24.0% | 24.8% | 23.2% | 26.0% | 27.7% | 29.7% | 29.7% | 26.1% |
| ROIC             | 17.7% | 14.7% | 24.0% | 24.8% | 23.2% | 26.0% | 27.7% | 29.7% | 29.7% | 21.7% |
| Shares Out.      | 51.2  | 51.5  | 51.5  | 51.8  | 51.8  | 51.8  | 52.3  | 51.6  | 51.6  | 51.24 |
| Revenue/Share    | 5.80  | 6.44  | 7.01  | 7.74  | 7.50  | 8.74  | 9.82  | 10.40 | 10.4  | 11.36 |
| FCF/Share        | 0.97  | 1.17  | 1.38  | 1.58  | 1.84  | ---   |       |       | NA    | 0     |

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.